Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5-a]pyrimidine-Based Inhibitors Targeting the DCN1–UBC12 Protein–Protein Interaction
Shuai Wang, Lijie Zhao, Xiaojing Shi, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 5, pp. 2772-2797
Closed Access | Times Cited: 71

Showing 26-50 of 71 citing articles:

Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity
Xin-Hui Zhang, Huiqin Kang, Yuanyuan Tao, et al.
European Journal of Medicinal Chemistry (2021) Vol. 218, pp. 113392-113392
Closed Access | Times Cited: 21
Discovery of [1,2,4]triazolo[1,5-a]pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors
Shuai Wang, Dandan Shen, Lijie Zhao, et al.
Chinese Chemical Letters (2019) Vol. 31, Iss. 2, pp. 418-422
Closed Access | Times Cited: 23
Discovery of 1,2,4-triazine dithiocarbamate derivatives as NEDDylation agonists to inhibit gastric cancers
Jian Song, Yuan Liu, Xin-Ying Yuan, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113801-113801
Closed Access | Times Cited: 20
Discovery of 1,2,4-triazine-based derivatives as novel neddylation inhibitors and anticancer activity studies against gastric cancer MGC-803 cells
Jian Song, Xinxin Cui, Bowen Wu, et al.
Bioorganic & Medicinal Chemistry Letters (2019) Vol. 30, Iss. 2, pp. 126791-126791
Closed Access | Times Cited: 21
Research progress of LSD1-based dual-target agents for cancer therapy
Xiaojuan Yang
Bioorganic & Medicinal Chemistry (2024) Vol. 101, pp. 117651-117651
Closed Access | Times Cited: 2
Analog of antiviral drug Triazavirin (Riamilovir) labeled with stable isotopes 13C and 15N. Synthesis and NMR characteristics
Tatyana S. Shestakova, Sergey L. Deev, Oleg S. Eltsov, et al.
Russian Chemical Bulletin (2024) Vol. 73, Iss. 2, pp. 372-378
Closed Access | Times Cited: 2
Discovery of 1,2,4-Triazole-3-thione Derivatives as Potent and Selective DCN1 Inhibitors for Pathological Cardiac Fibrosis and Remodeling
Zhangxu He, Ge Gao, Hui Qiao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 18699-18723
Closed Access | Times Cited: 2
Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor
Pengxing He, Sheng-Hui Niu, Shuai Wang, et al.
Acta Pharmaceutica Sinica B (2019) Vol. 9, Iss. 6, pp. 1193-1203
Open Access | Times Cited: 19
Discovery of new [1,2,4] Triazolo[1,5-a]Pyrimidine derivatives that Kill gastric cancer cells via the mitochondria pathway
Shuai Wang, Xubin Ma, Xiaohan Yuan, et al.
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112630-112630
Closed Access | Times Cited: 18
Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction
Wenjuan Zhou, Chenhao Xu, Guanjun Dong, et al.
European Journal of Medicinal Chemistry (2021) Vol. 217, pp. 113326-113326
Closed Access | Times Cited: 15
Design, synthesis and biological evaluation of new steroidal β-triazoly enones as potent antiproliferative agents
Jianwei Zhao, Jia–Wen Guo, Ming-Jie Huang, et al.
Steroids (2019) Vol. 150, pp. 108431-108431
Closed Access | Times Cited: 16
Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth in vitro and in vivo
Xin Chen, Xi Yang, Fei Mao, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112964-112964
Closed Access | Times Cited: 15
Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M
Ho Shin Kim, Jared T. Hammill, Daniel C. Scott, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 9, pp. 5850-5862
Open Access | Times Cited: 14
Mesomeric Betaines Based on Adamantylated 1,2,4‐Triazolo[4,3‐a]pyrimidin‐5‐ones: Synthesis, Structure and Conversion into Anionic N‐Heterocyclic Carbenes
Ekaterina S. Sheina, Tatyana S. Shestakova, Sergey L. Deev, et al.
Chemistry - An Asian Journal (2023) Vol. 18, Iss. 5
Closed Access | Times Cited: 5
Discovery of neddylation E2s inhibitors with therapeutic activity
MAA Mamun, Ying Liu, Yin-Ping Geng, et al.
Oncogenesis (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 5
Drug repurposing: Discovery of troxipide analogs as potent antitumor agents
Nan Lü, Jin-Ling Huo, Shuai Wang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 202, pp. 112471-112471
Open Access | Times Cited: 13
Cullin-RING Ligases as Promising Targets for Gastric Carcinoma Treatment
Qianqian Song, Siqi Feng, Wenjun Peng, et al.
Pharmacological Research (2021) Vol. 170, pp. 105493-105493
Closed Access | Times Cited: 12
Discovery of Potent and Selective 2-(Benzylthio)pyrimidine-based DCN1-UBC12 Inhibitors for Anticardiac Fibrotic Effects
Zhangxu He, Qi An, Bo Wei, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 1, pp. 163-190
Closed Access | Times Cited: 12
Discovery of tofacitinib derivatives as orally active antitumor agents based on the scaffold hybridization strategy
Xiaojing Shi, Shuai Wang, Xiaojing Li, et al.
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112601-112601
Closed Access | Times Cited: 12
Proapoptotic effect of WS-299 induced by NOXA accumulation and NRF2-counterbalanced oxidative stress damage through targeting RBX1-UBE2M interaction in gastric cancers
Ting Ma, Qianqian Song, Bing Cheng, et al.
Bioorganic Chemistry (2024) Vol. 144, pp. 107142-107142
Closed Access | Times Cited: 1
Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer
Anqi Li, Ting Ma, Shuai Wang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116240-116240
Open Access | Times Cited: 1
DCUN1D1 and neddylation: Potential targets for cancer therapy
Juliano D. Paccez, Chiara L.M. Foret, Jaira F. de Vasconcellos, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 7, pp. 167308-167308
Closed Access | Times Cited: 1
Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy
Xiangshuo Qin, Xin Han, Yi Sun
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117356-117356
Open Access | Times Cited: 1
Inhibiting Neddylation: A New Strategy for Tumor Therapy
Jian‐Jun Sun, Cui Liu, Changhui Lang, et al.
Journal of Pharmaceutical Analysis (2024), pp. 101140-101140
Open Access | Times Cited: 1
An overview of the most used synthetic pathways of 1,2,4-triazolo[1,5-a]pyrimidines
Mohamed Nabil Zedan, Mai E. Shoman, Mohamed Abdel‐Aziz, et al.
Results in Chemistry (2024) Vol. 12, pp. 101903-101903
Open Access | Times Cited: 1

Scroll to top